Form 8-K - Current report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest reported): July 19, 2024

Novo Integrated Sciences, Inc.

(Exact name of registrant as specified in its charter)

Nevada	001-40089	59-3691650
(State or other jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification Number)

11120 NE 2nd Street, Suite 100, Bellevue, WA 98004

(Address of principal executive offices)

(206) 617-9797

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.)

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CF$ 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on which Registered
Common Stock		NVOS		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On July 19, 2024, Novo Integrated Sciences, Inc. issued a press release announcing its financial results for the quarter ended May 31, 2024. A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information contained in the website is not a part of this Current Report on Form 8-K.

The information furnished pursuant to this Item 2.02, including the information contained in Exhibit 99.1, is “furnished” and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by the registrant on July 19, 2024.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Novo Integrated Sciences, Inc.

Dated: July 19, 2024	By:	/s/ Robert Mattacchione
		Robert Mattacchione
		Chief Executive Officer

Exhibit 99.1

Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results

BELLEVUE, Wash., July 19, 2024 - Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the third fiscal quarter ended May 31, 2024.

Robert Mattacchione, Novo’s CEO and Board Chairman, stated, “The Company’s fiscal year 2024 third quarter emphasized maximizing operational efficiencies for all business units. The Company continues to work with certain prospective financial partners to close previously announced non-traditional financing opportunities to raise foundational capital with repayment terms necessary to support and accelerate the further growth of Novo’s three-pillar business model. The Company remains committed to the commercialization of its proprietary product offerings and the expansion and delivery of its essential services and solutions for how non-catastrophic healthcare is delivered both now and in the future.”

Financial Highlights for the three-month period ended May 31, 2024:

	●	Cash and cash equivalents were $1,539,771, total assets were $35,327,000, total liabilities were $25,663,779, and total stockholders’ equity was $9,956,134.

	●	Revenues were $3,151,851, representing a decrease of $141,082, or 4%, from $3,292,933 for the three months ended May 31, 2023. The decrease in revenue is principally due to a decrease in product sales. Acenzia’s and Terragenx’s revenue for the three months ended May 31, 2024 were $884,396 and $103,399, respectively. Despite a decrease in total revenue, revenue from our healthcare services increased by 8.1% when comparing the revenue for the three months ended May 31, 2024 to the three months ended May 31, 2023.

	●	Operating costs were $3,417,096, representing an increase of $672,584, or 25%, from $2,744,512 for the three months ended May 31, 2023. The increase in operating costs was primarily due to the inflationary impact on operating costs.

	●	Net loss attributed to the Company was $13,741,903, representing an increase of $12,244,573, or 818%, from $1,497,330 for the three months ended May 31, 2023. The increase in net loss of $12,244,573 is mainly attributed to the recognition of a $6,724,690 loss in the fair value of the derivative liability, loss from operations of $1,089,785, amortization of the debt discount of $ 2,748,793 and foreign currency exchange loss of $1,455,248 arising as a result of intercompany balance reconciliation.

	●	On April 5, 2024, the Company executed a $6.21 million Securities Purchase Agreement and Promissory Note with Streeterville Capital LLC (the “Streeterville Note”). The interest rate on the Streeterville Note is 10.9% and it has a 12-month maturity date. A portion of the proceeds from the Streeterville Note paid the balance owed on two notes, as follows:

	○	$3,228,774 (principal) and $30,571.28 (interest) on the 2023 $3.5 million Mast Hill note; and

	○	$82,761 (principal) and $1,552 (interest) on the 2023 $277,777 First Fire note.

About Novo Integrated Sciences, Inc.

Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver, these services and products through the integration of medical technology, advanced therapeutics, and rehabilitative science.

We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution.

The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers:

	●	First Pillar: Service Networks. Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities.

	●	Second Pillar: Technology. Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home.

	●	Third Pillar: Products. Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions.

Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting-edge advancement in patient-first platforms.

For more information concerning Novo Integrated Sciences, please visit www.novointegrated.com.

Twitter, LinkedIn, Facebook, Instagram, YouTube

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as “believe,” “intend,” “expect,” “anticipate,” “plan,” “potential,” “continue” or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties are discussed in Novo’s filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond Novo’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Novo’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Novo assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein.

Contact

Chris David, COO-President

Novo Integrated Sciences, Inc.

chris.david@novointegrated.com

(888) 512-1195

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

As of May 31, 2024 (unaudited) and August 31, 2023

	May 31,			August 31,
	2024			2023
ASSETS

Current Assets:
Cash and cash equivalents	$	1,539,771		$	416,323
Accounts receivable, net		2,251,528			1,467,028
Inventory, net		1,112,068			1,106,983
Other receivables, current portion		1,043,473			1,051,584
Prepaid expenses and other current assets		214,436			346,171
Total current assets		6,161,276			4,388,089

Property and equipment, net		5,157,781			5,390,038
Intangible assets, net		14,690,038			16,218,539
Right-of-use assets, net		1,793,907			1,983,898
Goodwill		7,523,998			7,582,483
TOTAL ASSETS	$	35,327,000		$	35,563,047

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities:
Accounts payable	$	3,894,602		$	3,513,842
Accrued expenses		1,332,485			1,233,549
Accrued interest (including amounts to related parties)		450,795			382,666
Government loans and notes payable, current portion		93,488			277,405
Convertible notes payable, net of discount of $4,985,381		1,224,619			558,668
Derivative liability		14,048,576			–
Contingent liability		45,968			61,767
Debentures, related parties		909,753			916,824
Due to related parties		262,295			533,001
Finance lease liability, net of current portion		4,336			11,744
Operating lease liability, current portion		409,516			415,392
Total current liabilities		22,676,433			7,904,858

Government loans and notes payable, net of current portion		63,572			65,038
Operating lease liability, net of current portion		1,534,078			1,693,577
Deferred tax liability		1,389,696			1,400,499
TOTAL LIABILITIES		25,663,779			11,063,972

Commitments and contingencies		–			–

STOCKHOLDERS’ EQUITY
Novo Integrated Sciences, Inc.
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; Nil shares issued and outstanding at May 31, 2024 and August 31, 2023		–			–
Common stock; $0.001 par value; 499,000,000 shares authorized; 19,054,523 and 15,759,325 shares issued and outstanding at May 31, 2024 and August 31, 2023, respectively		19,055			15,760
Additional paid-in capital		96,660,608			90,973,316
Common stock to be issued (1,700 and 91,138 shares at May 31, 2024 and August 31, 2023)		25,500			1,217,293
Other comprehensive (loss) income		1,452,386			(357,383	)
Accumulated deficit		(88,201,415	)		(67,033,041	)
Total Novo Integrated Sciences, Inc. stockholders’ equity		9,956,134			24,815,945
Noncontrolling interest		(292,913	)		(316,870	)
Total stockholders’ equity		9,663,221			24,499,075
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	35,327,000		$	35,563,047

* The condensed consolidated balance sheets’ common stock amounts have been retroactively adjusted to account for the Company’s 1:10 reverse stock split, effective November 7, 2023.

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

For the Three and Nine Months Ended May 31, 2024 and 2023 (unaudited)

	Three Months Ended						Nine Months Ended
	May 31,			May 31,			May 31,			May 31,
	2024			2023			2024			2023
	(unaudited)			(unaudited)			(unaudited)			(unaudited)
Revenues	$	3,151,851		$	3,292,933		$	10,213,661		$	9,268,722

Cost of revenues		2,254,958			1,978,839			6,048,664			5,244,192

Gross profit		896,893			1,314,094			4,164,997			4,024,530

Operating expenses:
Selling expenses		2,635			1,877			14,811			9,916
General and administrative expenses		3,414,461			2,742,635			11,527,794			9,473,802
Total operating expenses		3,417,096			2,744,512			11,542,605			9,483,718

Loss from operations		(2,520,203	)		(1,430,418	)		(7,377,608	)		(5,459,188	)

Non operating income (expense)
Interest income		2,214			62,397			6,910			6,762
Interest expense		(178,445	)		(9,570	)		(460,503	)		(240,520	)
Other expense		(3,431	)		–			(964,368	)		–
Change in fair value of derivative liability		(6,724,690	)		–			(5,765,822	)		–
Amortization of debt discount		(2,904,830	)		(156,037	)		(5,095,331	)		(4,386,899	)
Exchange currency (loss) gain		(1,406,915	)		48,333			(1,485,861	)		12,652
Total other expense		(11,216,097	)		(54,877	)		(13,764,975	)		(4,608,005	)

Loss before income taxes		(13,736,300	)		(1,485,295	)		(21,142,583	)		(10,067,193	)

Income tax expense		–			–			–			–

Net loss	$	(13,736,300	)	$	(1,485,295	)	$	(21,142,583	)	$	(10,067,193	)

Net income (loss) attributed to noncontrolling interest		5,603			12,035			25,791			(13,095	)

Net loss attributed to Novo Integrated Sciences, Inc.	$	(13,741,903	)	$	(1,497,330	)	$	(21,168,374	)	$	(10,054,098	)

Comprehensive loss:
Net loss		(13,736,300	)		(1,485,295	)		(21,142,583	)		(10,067,193	)
Foreign currency translation gain (loss)		750,067			(120,357	)		1,809,769			(738,022	)
Comprehensive loss:	$	(12,986,233	)	$	(1,605,652	)	$	(19,332,814	)	$	(10,805,215	)

Weighted average common shares outstanding - basic and diluted		18,685,979			14,360,058			17,688,692			8,583,229

Net loss per common share - basic and diluted	$	(0.74	)	$	(0.10	)	$	(1.20	)	$	(1.17	)

* The condensed consolidated statements of operations and comprehensive loss’s share and per share amounts have been retroactively adjusted to account for the Company’s 1:10 reverse stock split, effective November 7, 2023.

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

For the Three and Nine Months Ended May 31, 2024 and 2023 (unaudited)

	Common Stock				Additional Paid-in			Common Stock To			Other Comprehensive			Accumulated			Total Novo Stockholders’			Noncontrolling			Total
	Shares		Amount		Capital			Be Issued			Income			Deficit			Equity			Interest			Equity

Balance, August 31, 2023		15,759,325	$	15,760	$	90,973,316		$	1,217,293		$	(357,383	)	$	(67,033,041	)	$	24,815,945		$	(316,870	)	$	24,499,075

Cashless exercise of warrants		245,802		246		1,323,152			–			–			–			1,323,398			–			1,323,398
Exercise of warrants for cash		240,400		240		240,160			–			–			–			240,400			–			240,400
Share issuance for convertible debt settlement		519,845		520		577,002			–			–			–			577,522			–			577,522
Issuance of common stock to be issued		73,767		74		1,172,776			(1,172,850	)		–			–			–			–			–
Common stock issued for services		424,080		424		1,194,976			–			–			–			1,195,400			–			1,195,400
Reverse stock split share rounding		27,973		28		(28	)		–			–			–			–			–			–
Foreign currency translation gain		–		–		–			–			110,895			–			110,895			(1,919	)		108,976
Net loss		–		–		–			–			–			(4,680,343	)		(4,680,343	)		19,620			(4,660,723	)

Balance, November 30, 2023		17,291,192	$	17,292	$	95,481,354		$	44,443		$	(246,488	)	$	(71,713,384	)	$	23,583,217		$	(299,169	)	$	23,284,048

Share issuance for convertible debt settlement		457,128		457		453,616			–			–			–			454,073			–			454,073
Foreign currency translation gain		–		–		–			–			749,869			–			749,869			198			750,067
Fair value of stock options		–		–		147,656			–			–			–			147,656			–			147,656
Net loss		–		–		–			–			–			(2,746,128	)		(2,746,128	)		568			(2,745,560	)

Balance, February 29, 2024		17,748,320	$	17,749	$	96,082,626		$	44,443		$	503,381		$	(74,459,512	)	$	22,188,687		$	(298,403	)	$	21,890,284

Share issuance for convertible debt settlement		1,306,203		1,306		577,982			–			–			–			579,288			–			579,288
Cancellation of agreement		–		–		–			(18,943	)		–			–			(18,943	)		–			(18,943	)
Foreign currency translation gain		–		–		–			–			949,005			–			949,005			(113	)		948,892
Net loss		–		–		–			–			–			(13,741,903	)		(13,741,903	)		5,603			(13,736,300	)

Balance, May 31, 2024		19,054,523	$	19,055	$	96,660,608		$	25,500		$	1,452,386		$	(88,201,415	)	$	9,956,134		$	(292,913	)	$	9,663,221

	Common Stock				Additional Paid-in		Common Stock To			Other Comprehensive			Accumulated			Total Novo Stockholders’			Noncontrolling			Total
	Shares		Amount		Capital		Be Issued			Income			Deficit			Equity			Interest			Equity

Balance, August 31, 2022		3,118,063	$	3,118	$	66,084,887	$	9,474,807		$	560,836		$	(53,818,489	)	$	22,305,159		$	(257,588	)	$	22,047,571

Common stock issued for cash, net of offering costs		400,000		400		1,794,600		–			–			–			1,795,000			–			1,795,000
Issuance of common stock to be issued		3,623		4		92,362		(92,366	)		–			–			–			–			–
Cashless exercise of warrants		467,399		467		1,138,583		–			–			–			1,139,050			–			1,139,050
Fair value of stock options		–		–		60,887		–			–			–			60,887			–			60,887
Foreign currency translation loss		–		–		–		–			(417,008	)		–			(417,008	)		(3,974	)		(420,982	)
Net loss		–		–		–		–			–			(3,935,413	)		(3,935,413	)		(1,323	)		(3,936,736	)

Balance, November 30, 2022		3,989,085	$	3,989	$	69,171,319	$	9,382,441		$	143,828		$	(57,753,902	)	$	20,947,675		$	(262,885	)	$	20,684,790

Share issuance for convertible debt settlement		9,310,940		9,311		9,076,740		–			–			–			9,086,051			–			9,086,051
Exercise of warrants (Cashless Exercise)		115,935		116		282,417		–			–			–			282,533			–			282,533
Exercise of warrants for cash		131,000		131		130,869		–			–			–			131,000			–			131,000
Issuance of common stock to be issued		320,202		320		8,164,828		(8,165,148	)		–			–			–			–			–
Shares issued with convertible notes		95,500		96		82,868		–			–			–			82,963			–			82,963
Value of warrants issued with convertible notes		–		–		86,327		–			–			–			86,327			–			86,327
Fair value of stock options		–		–		60,887		–			–			–			60,887			–			60,887
Extinguishment of derivative liability due to conversion		–		–		1,390,380		–			–			–			1,390,380			–			1,390,380
Foreign currency translation loss		–		–		–		–			(195,821	)		–			(195,821	)		(862	)		(196,683	)
Net loss		–		–		–		–			–			(4,621,355	)		(4,621,355	)		(23,807	)		(4,645,162	)

Balance, February 28, 2023		13,962,662		13,963		88,446,635		1,217,293			(51,993	)		(62,375,257	)		27,250,640			(287,554	)		26,963,086


Share issuance for convertible debt settlement		107,594		108		100,170		–			–			–			100,278			–			100,278
Exercise of warrants for cash		320,000		320		319,680		–			–			–			320,000			–			320,000
Shares issued with convertible notes		95,500		96		90,037		–			–			–			90,132			–			90,132
Value of warrants issued with convertible notes		–		–		93,811		–			–			–			93,811			–			93,811
Beneficial conversion feature upon issuance of convertible debt		–		–		66,068		–			–			–			66,068			–			66,068
Stock option expense		–		–		263,561		–			–			–			263,561			–			263,561
Foreign currency translation loss		–		–		–		–			(120,533	)		–			(120,533	)		176			(120,357	)
Net loss		–		–		–		–			–			(1,497,330	)		(1,497,330	)		12,035			(1,485,295	)

Balance, May 31, 2023		14,485,756	$	14,486	$	89,379,961	$	1,217,293		$	(172,526	)	$	(63,872,587	)	$	26,566,627		$	(275,343	)	$	26,291,284

* The condensed consolidated statements of stockholders’ equity share amounts have been retroactively adjusted to account for the Company’s 1:10 reverse stock split, effective November 7, 2023.

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Nine Months Ended May 31, 2024 and 2023 (unaudited)

	Nine Months Ended
	May 31,			May 31,
	2024			2023
	(unaudited)			(unaudited)

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(21,142,583	)	$	(10,067,193	)
Adjustments for non-cash items:
Depreciation and amortization		1,697,317			1,718,388
Fair value of vested stock options		147,656			385,335
Change in fair value of derivative liability		5,765,822			–
Cashless exercise of warrants		1,323,398			1,421,583
Common stock issued for services		1,195,400			–
Operating lease expense		466,276			624,246
Amortization of debt discount		5,095,331			4,386,899
Foreign currency transaction losses		1,485,861			(12,652	)
Changes in operating assets and liabilities:
Accounts receivable		(797,692	)		(308,907	)
Inventory		(12,548	)		(92,260	)
Prepaid expenses and other current assets		130,015			333,724
Accounts payable		408,067			154,542
Accrued expenses		76,428			104,004
Accrued interest		103,605			(67,634	)
Operating lease liability		(466,276	)		(594,618	)
Net cash used in operating activities		(4,523,923	)		(2,014,543	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(2,005	)		(18,870	)
Net cash used in investing activities		(2,005	)		(18,870	)

CASH FLOWS FROM FINANCING ACTIVITIES:
(Repayments to) proceeds from related parties		(267,756	)		(56,649	)
Proceeds from notes payable		274			222,000
Repayments of notes payable		(184,125	)		–
Repayments of finance leases		(7,350	)		(6,435	)
Proceeds from issuance of convertible notes, net		8,649,153			925,306
Repayment of convertible notes		(3,311,536	)		(3,033,888	)
Proceeds from the sale of common stock, net of offering costs		–			1,795,000
Proceeds from exercise of warrants		240,400			451,000
Net cash provided by financing activities		5,119,060			296,334

Effect of exchange rate changes on cash and cash equivalents		530,316			22,403

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		1,123,448			(1,714,676	)

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		416,323			2,178,687

CASH AND CASH EQUIVALENTS, END OF PERIOD	$	1,539,771		$	464,011

CASH PAID FOR:
Interest	$	190,491		$	343,878
Income taxes	$	–		$	–

SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Common stock issued for convertible debt settlement	$	1,610,883		$	9,186,329
Beneficial conversion feature upon issuance of convertible notes		–			66,068
Debt discount recognized on derivative liability		–			1,390,380
Debt discount recognized on convertible note		–			639,993
Extinguishment of derivative liability due to conversion		–			1,390,380
Common stock issued with convertible notes		–			173,095
Warrants issued with convertible notes	$	–		$	180,138

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

Cover	Jul. 19, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jul. 19, 2024
Entity File Number	001-40089
Entity Registrant Name	Novo Integrated Sciences, Inc.
Entity Central Index Key	0001138978
Entity Tax Identification Number	59-3691650
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	11120 NE 2nd Street
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Bellevue
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98004
City Area Code	(206)
Local Phone Number	617-9797
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	NVOS
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false